2658-6533Научные результаты биомедицинских исследований2658-653310.18413/2658-6533-2021-7-3-0-62483Фармакология, клиническая фармакология<strong>Correction of hypertensive retinal changes in rats with Semax</strong><strong>Correction of hypertensive retinal changes in rats with Semax</strong>LugovskoySergey S.LugovskoySergey S.lug90@mail.ruChernyaevaSofia S.ChernyaevaSofia S.sonyachernyaeva@yandex.ruPeresypkinaAnna A.PeresypkinaAnna A.peresypkina_a@bsu.edu.ruPobedaAnna S.PobedaAnna S.pobeda@bsu.edu.ruSolovevNikolai V.SolovevNikolai V.morkovkapro@mail.ruShchurovskayaKristina V.ShchurovskayaKristina V.kristinka-i@yandex.ruIezhitsaIgor N.IezhitsaIgor N.iezhitsa@yandex.ru20217300

Background:&nbsp;Currently, there are no drugs for the specific treatment of hypertensive retinal changes. The main therapy is for the treatment of a systemic disease &ndash; hypertensive disease.&nbsp;Therefore, the search for ways of specific pharmacological correction of hypertensive retinal changes is of great interest. The aim of the study:&nbsp;To evaluate the correction possibility of retinal injuries with Semax in a rat model of hypertensive neuroretinopathy. Materials and methods:&nbsp;The model was performed by injection of N-nitro-L-arginine methyl ester (L-NAME) at a dose of 1.25 mg/100 g of rat mass within 28 days and a single increase in intraocular pressure (IOP) to 110 mmHg for 5 min. The retinoprotective effect of Semax at a dose of 7.2 &mu;g/100 g of rat mass, in comparison with Picamilon at a dose of 3 mg/100 g of rat mass, was estimated by laser Doppler flowmetry (LDF) and electroretinography (ERG). Results:&nbsp;The use of Semax led to an increase in retinal perfusion by 62.7%, p &lt; 0.05, in comparison with the group with the model, and by 9.9%, p &lt; 0.05, in comparison with Picamilon; an increase in the b/a coefficient by 31.4% in comparison with the group with the model, p &lt; 0.05, and by 14.6%, p &lt; 0.05 in comparison with Picamilon. Conclusion:&nbsp;The neuroretinoprotective effect of Semax in correction of hypertensive retinal changes in rats may be due to the presence of neuroprotective, neurometabolic, antioxidant and endothelioprotective effects in Semax. Thus, Semax can be a promising agent in hypertensive neuroretinopathy treatment.

Background:&nbsp;Currently, there are no drugs for the specific treatment of hypertensive retinal changes. The main therapy is for the treatment of a systemic disease &ndash; hypertensive disease.&nbsp;Therefore, the search for ways of specific pharmacological correction of hypertensive retinal changes is of great interest. The aim of the study:&nbsp;To evaluate the correction possibility of retinal injuries with Semax in a rat model of hypertensive neuroretinopathy. Materials and methods:&nbsp;The model was performed by injection of N-nitro-L-arginine methyl ester (L-NAME) at a dose of 1.25 mg/100 g of rat mass within 28 days and a single increase in intraocular pressure (IOP) to 110 mmHg for 5 min. The retinoprotective effect of Semax at a dose of 7.2 &mu;g/100 g of rat mass, in comparison with Picamilon at a dose of 3 mg/100 g of rat mass, was estimated by laser Doppler flowmetry (LDF) and electroretinography (ERG). Results:&nbsp;The use of Semax led to an increase in retinal perfusion by 62.7%, p &lt; 0.05, in comparison with the group with the model, and by 9.9%, p &lt; 0.05, in comparison with Picamilon; an increase in the b/a coefficient by 31.4% in comparison with the group with the model, p &lt; 0.05, and by 14.6%, p &lt; 0.05 in comparison with Picamilon. Conclusion:&nbsp;The neuroretinoprotective effect of Semax in correction of hypertensive retinal changes in rats may be due to the presence of neuroprotective, neurometabolic, antioxidant and endothelioprotective effects in Semax. Thus, Semax can be a promising agent in hypertensive neuroretinopathy treatment.

Semaxhypertensive neuroretinopathyratslaser doppler flowmetryelectroretinographySemaxhypertensive neuroretinopathyratslaser doppler flowmetryelectroretinographyСписок литературыFraser-Bell S, Symes R, Vaze A. Hypertensive eye disease: a review. Clinical and Experimental Ophthalmology. 2017;45(1):45-53. DOI: https://doi.org/10.1111/ceo.12905Akbar S, Akram MU, Sharif M, et al. Arteriovenous ratio and papilledema based hybrid decision support system for detection and grading of hypertensive retinopathy. Computer Methods and Programs in Biomedicine. 2018;154:123-141. DOI: https://doi.org/10.1016/j.cmpb.2017.11.014Stryjewski TP, Papakostas TD, Vavvas D. Proliferative Hypertensive Retinopathy. Journal of the American Medical Association ophthalmology. 2016;134(3):345-346. DOI: https://doi.org/10.1001/jamaophthalmol.2015.5583Peresypkina A, Pazhinsky A, Danilenko L, et al. Retinoprotective Effect of 2-Ethyl-3-hydroxy-6-methylpyridine Nicotinate. Biology (Basel). 2020;9(3):45. DOI: https://doi.org/10.3390/biology9030045Bhargava M, Ikram MK, Wong TY. How does hypertension affect your eyes? Journal of human hypertension. 2012;26(2):71-83. DOI: https://doi.org/10.1038/jhh.2011.37Konstantinidis L. Hypertension and the eye. Current Opinion in Ophthalmology. 2016;27(6):514-521. DOI: https://doi.org/10.1097/ICU.0000000000000307Kolman SAM, van Sijl AM, van der Sluijs FA, et al. Consideration of hypertensive retinopathy as an important end-organ damage in patients with hypertension. Journal of Human Hypertension. 2017;31(2):121-125. DOI: https://doi.org/10.1038/jhh.2016.49Antsiferov OV, Korokin MV, Gureev VV, et al. Eleven-amino acid peptides that mimic the erythropoietin &alpha;-helix B increases cell survival in endotheliocyte culture. Archivos Venezolanos de Farmacologia y Terapeutica. 2020;39(5):533&ndash;537. DOI: https://doi.org/10.5281/zenodo.4155554Golubev IV, Gureev VV, Korokin MV, et al. Endothelial protective properties of short-chain peptides that mimic &alpha;-helix b of erythropoietin in experimental preeclampsia. Archivos Venezolanos de Farmacologia y Terapeutica. 2020;39(5):573-577. DOI: https://doi.org/10.5281/zenodo.4265179Korokin M, Gureev V, Gudyrev O, et al. Erythropoietin Mimetic Peptide (pHBSP) Corrects Endothelial Dysfunction in a Rat Model of Preeclampsia. International Journal of Molecular Sciences. 2020;21(18):6759. DOI: https://doi.org/10.3390/ijms21186759Pokrovskii MV, Soldatov VO, Zatolokina MA, et al. Relation of EPOR/CD131-mediated neuroprotection with modulated gene expression of autophagy, apoptosis, neuroinflammation and neural regeneration in rats under chronic ethanol exposure conditions. Experimental and Clinical Pharmacology. 2021;84(2):91-98. DOI: https://doi.org/10.30906/0869-2092-2021-84-2-91-98Korokin MV, Soldatov VO, Tietze AA, et al. 11-amino acid peptide imitating the structure of erythropoietin &alpha;-helix b improves endothelial function, but stimulates thrombosis in rats. Pharmacy &amp; Pharmacology. 2019;7(6):312-320. DOI: https://doi.org/10.19163/2307-9266-2019-7-6-312-320Gusev EI, Martynov MY, Kostenko EV, et al. The efficacy of Semax in the tretament of patients at different stages of ischemic stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018;118(3. Vyp. 2):61-68. Russian. DOI: https://doi.org/10.17116/jnevro20181183261-68Medvedeva EV, Dmitrieva VG, Limborska SA, et al. Semax, an analog of ACTH((4-7)), regulates expression of immune response genes during ischemic brain injury in rats. Molecular Genetics and Genomics. 2017;292(3):635-653. DOI: https://doi.org/10.1007/s00438-017-1297-1Glazova NY, Manchenko DM, Volodina MA, et al. Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. Neuropeptides. 2020;86:102114. DOI: https://doi.org/10.1016/j.npep.2020.102114Storozhevykh TP, Tukhbatova GR, Senilova YE, et al. Effects of Semax and its Pro-Gly-Pro fragment on calcium homeostasis of neurons and their survival under conditions of glutamate toxicity. Bulletin of Experimental Biology and Medicine. 2007;143(5):601-604. DOI: 10.1007/s10517-007-0192-xPolunin GS, Nurieva SM, Baiandin DL, et al. Evaluation of therapeutic effect of new Russian drug Semax in optic nerve disease. Vestnik Oftalmologii. 2000; 116(1):15-18. Russian.Dolotov OV, Zolotarev IA, Dorokhova EM, et al. The binding of Semax, ACTH 4&ndash;10 heptapeptide, to plasma membranes of the rat forebrain basal nuclei and its biodegradation. Russian Journal of Bioorganic Chemistry. 2004;30(3):241-246. Russian. DOI: http://doi.org/10.1023/b:rubi.0000030127.46845.f0Martynova KV, Andreeva LA, Klimova PA, et al. Structural-functional study of glycine-and-proline-containing peptides (glyprolines) as potential neuroprotectors. Russian Journal of Bioorganic Chemistry. 2009;35(2):165-171. DOI: http://doi.org/10.1134/s1068162009020022Stavchansky VV, Yuzhakov VV, Botsina AY, et al. The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study. Journal of Molecular Neuroscience. 2011;45(2):177-185. DOI: http://doi.org/10.1007/s12031-010-9421-2Filippenkov IB, Stavchansky VV, Denisova AE, et al. Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia&ndash;Reperfusion in Rats. Genes. 2020;11:681. DOI: https://doi.org/10.3390/genes11060681Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Molecular Neurobiology. 2015;53:1181-1194. DOI: http://doi.org/10.1007/s12035-014-9070-5Shakova FM, Kirova YI, Silachev DN, et al. Protective Effects of PGC-1&alpha; Activators on Ischemic Stroke in a Rat Model of Photochemically Induced Thrombosis. Brain Sciences. 2021;11:325. DOI: https://doi.org/10.3390/brainsci11030325Elagina AA, Lyashev YuD, Artyushkova EB, et al. Peptide preparations protect endothelium against dysfunction caused by diabetes mellitus. Experimental and Clinical Pharmacology. 2020;83(11):12-15. Russian. DOI: http://doi.org/10.30906/0869-2092-2020-83-11-12-15Elagina AA, Lyashev YuD, Artyushkova EB, et al. Antioxidant effect of peptide drugs in diabetes mellitus. Vestnik NovSU. 2020;4(120):70-74. Russian. DOI: https://doi.org/10.34680/2076-8052.2020.4(120).70-74.Gubareva VO, Pazhinsky AL, Zhernakova NI, et al. Protective effects of 11-amino acid darbepoetin fragment in the experimental hypertensive neuroretinopathy. Drug Invention Today. 2019;12(11):2726-2730.Alrashdi SF, Deliyanti D, Wilkinson-Berka JL. . Experimental Eye Research. 2018;176:1-9. DOI: https://doi.org/10.1016/j.exer.2018.06.025Reichhart N, Haase N, Crespo-Garcia S, et al. . Clinical Science. 2016;130(13):1075-1088. DOI: https://doi.org/10.1042/CS20160092Li Y, Wang Q, Muir ER, et al. . Current Eye Research. 2020;45(11):1422-1429. DOI: https://doi.org/10.1080/02713683.2020.1752738McDonald L, Lee GR, Degooyer TE, et al. Ophthalmic Research. 2010;43(2):99-107. DOI: https://doi.org/10.1159/000247594Peresypkina AA, Pazhinsky AL, Pobeda AS, et al. The development of hypertensive neuroretinopathy model. Indo American journal of pharmaceutical sciences. 2017;4(10):3695-3700. DOI: http://doi.org/10.5281/zenodo.1019417Vidal [Internet]. [cited 2021 March 19]. Available from: https://www.vidal.ru/drugs/Semax__28676Creel DJ. Electroretinograms. Handbook of Clinical Neurology. 2019;160:481-493. DOI: http://doi.org/10.1016/B978-0-444-64032-1.00032-1Peresypkina AA, Pokrovskii MV, Gubareva VO, et al. Protective effect of carbamylated darbepoetin on the model of ischemic neuropathy of the optic nerve in rats. Experimental and Clinical Pharmacology. 2018;81:8-13. Russian. DOI: http://doi.org/10.30906/0869-2092-2018-81-7-8-13Сooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation. 2004;109(7):1813-1818. DOI: 10.1161/01.CIR.0000126823.07732.D5